DENVER, Sept. 14 /PRNewswire/ -- Enobia Pharma today announced positive data
from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy,
under investigation for the treatment of hypophosphatasia (HPP). After six
months of treatment with ENB-0040, four of five severely affected patients
showed marked improvements in bone mineralization, correction of skeletal
defects, better respiratory function, including weaning from assisted
ventilation, and cognitive and motor development. These findings were
presented by Dr. Michael Whyte at the 31(st) Annual Meeting of the American
Society for Bone and Mineral Research in Denver, CO.
